High Prevalence of Pulmonary Arterial Hypertension and Emergence of Covid-19 to Augment Growth of Iloprost Drugs Market
Iloprost is used for the treatment of certain kinds of pulmonary arterial hypertension. It is antithrombotic, anti-inflammatory, and antifibrotic. An inhaled formulation of iloprost, sold as Ventavis, is approved by the FDA for the treatment of pulmonary arterial hypertension. Market Dynamics High prevalence of pulmonary arterial hypertension is expected to propel growth of the iloprost drugs market. For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. Moreover, R&D in iloprost is also expected to aid in the growth of the market. For instance, in October 2020, CiVi Biopharma resumed patient enrollment for a Phase 3 trial testing iloprost, know...